Fig. 3From: A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycinToxin B concentrations (ng/mL) of individual patients in the fidaxomicin (a) and vancomycin (b) groups at each time point. *Only patients with detectable toxin B concentration at any point are presented. Subjects 5, 12, and 3 had CDI recurrence; whereas subject 33 had asymptomatic colonizationBack to article page